Pl(A2) polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury
about
sameAs
A novel adaptation of the integrin PSI domain revealed from its crystal structurePersonalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomicsAspirin and clopidogrel resistance: an emerging clinical entityAntithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actionsAspirin resistance in coronary artery disease is correlated to elevated markers for oxidative stress but not to the expression of cyclooxygenase (COX) 1/2, a novel COX-1 polymorphism or the PlA(1/2) polymorphismExploratory aspirin resistance trial in healthy Japanese volunteers (J-ART) using platelet aggregation as a measure of thrombogenicityPlatelet fragmentation requires a specific structural conformation of human monoclonal antibody against beta3 integrin.Pro32Pro33 mutations in the integrin β3 PSI domain result in αIIbβ3 priming and enhanced adhesion: reversal of the hypercoagulability phenotype by the Src inhibitor SKI-606.The PlA1/A2 polymorphism of glycoprotein IIIa as a risk factor for stroke: a systematic review and meta-analysis.The PlA1/A2 polymorphism of glycoprotein IIIa as a risk factor for myocardial infarction: a meta-analysis.Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group.The Leu33Pro polymorphism in the ITGB3 gene does not modify BRCA1/2-associated breast or ovarian cancer risks: results from a multicenter study among 15,542 BRCA1 and BRCA2 mutation carriers.Blood coagulation dynamics in haemostasis.Genetics of platelet glycoprotein receptors: risk of thrombotic events and pharmacogenetic implications.Antiplatelet drug resistance: not ready for prime time.Molecular mechanisms of prothrombotic risk due to genetic variations in platelet genes: Enhanced outside-in signaling through the Pro33 variant of integrin beta3.Genetics of coagulation: considerations for cardiac surgery.Hyperglycemia is associated with enhanced thrombin formation, platelet activation, and fibrin clot resistance to lysis in patients with acute coronary syndrome.Pharmacogenomics of platelet responsiveness to aspirin.Systemic blood coagulation activation in acute coronary syndromes.Pharmacogenetics of aspirin resistance: a comprehensive systematic review.Pharmacogenetics of cardiovascular drug therapy.Prospective, observational study of antiplatelet and coagulation biomarkers as predictors of thromboembolic events after implantation of ventricular assist devices.Stroke pharmacogenomics.Antiplatelet drug therapy: role of pharmacodynamic and genetic testing.The PlA1/A2 polymorphism of glycoprotein IIIa in relation to efficacy of antiplatelet drugs: a systematic review and meta-analysis.High on-treatment platelet reactivity in peripheral endovascular procedures.Association of platelet glycoprotein receptor alpha2beta1 integrin and glycoprotein IIIa gene polymorphisms with diabetic retinopathy: evidence from 3007 subjects.Why does aspirin decrease the risk of venous thromboembolism? On old and novel antithrombotic effects of acetyl salicylic acid.Sticky platelet syndrome: an important cause of life-threatening thrombotic complications.The glycoprotein IIIa gene polymorphism and the risk of myocardial infarction.Integrin beta3 Leu33Pro polymorphism increases BRCA1-associated ovarian cancer risk.Variation in ITGB3 is associated with asthma and sensitization to mold allergen in four populations.Genome-wide association study identifies ITGB3 as a QTL for whole blood serotonin.Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting.Aspirin and the prevention of venous thromboembolism following total joint arthroplasty: commonly asked questions.A1/A2 polymorphism of the glycoprotein IIIa gene and diabetic retinopathy in Caucasians with type 2 diabetes.
P2860
Q24300709-F421FF2D-92F2-47B8-8792-BC6BBACE164FQ26822796-BFEE5880-5FA2-4BA3-B3EA-819950AF1AF5Q28194021-BC704E7E-77DF-431D-8251-F704EC7C0CAEQ28211940-70562A99-5891-40CB-9FAC-686952F53231Q28217995-8677E4FF-EEF8-40E3-BEAB-A9D14303B113Q28218177-3137BCFB-42D2-4B16-9C5E-9B97A96CFB06Q33308465-C897209E-01DF-49E0-BD33-095E0ECA2F1EQ33584613-1BC73B27-516E-4348-99D2-0235C9DA09BDQ33836873-CA0F3BC2-503B-467A-9956-2F9A8ACA48C7Q33838453-4E92A732-89D1-40B7-AAE7-949CB83FAB2FQ33863833-20236F7B-58CE-4D7B-8962-BA2CC678824EQ34800968-CADEFA01-6A98-422D-9B89-84CB56F222DCQ35154489-15C89A92-887F-4C2E-A9CF-653D416258FFQ36094351-C17B357F-14F9-41FF-B148-AD621D7276B6Q36289432-C9E70993-F2FC-4188-AFBD-46260E8DC2C3Q36459045-5E364108-9D60-468C-8E40-C370F13EE40FQ36697910-F088D876-DDA8-4217-8DC1-FC114B7EB3A4Q36807512-4CC42D89-93ED-4DFC-8D52-2565EACD6364Q36989841-70DBDA63-3E65-4261-BAD1-3E6AEF17D6A4Q37116951-BF166F95-DDA5-4E2E-8EF6-9EEDB267A954Q37145122-5B32B53A-5DE6-4E6A-9318-A0176760B935Q37430401-D706D8EC-4305-4036-9CE4-8F09729EE065Q37479004-5C259867-A268-4381-B8B0-795CCBB39B9EQ37635110-F114DE1B-8DA5-4C0B-AD8F-7875D9E02AC5Q37882712-F4F7EB9C-80ED-4192-A332-B89376B22FC8Q38120047-D95F7DBE-0F68-46C7-A543-E94FF936ADF0Q38125134-4D613492-5E2D-4693-ABE8-A49674C74A94Q38224669-FD490AED-F92A-4064-9621-14D7C1268065Q38248477-4E824C8D-F535-4C99-910A-5F1970AC1468Q38633142-3CDED5B4-9DFB-49C6-90BF-9A3D6C6AF913Q40442876-672321DB-E68E-4EC1-A7B7-181E5D1FF958Q42550934-7C941518-2CC2-4148-A013-C4137525458FQ42639219-4E3FB9E3-2002-442F-B531-42E7E1CAAC24Q45006440-8412559A-0AC5-4A7A-8FB9-8FA32C58F6F4Q46909934-6D3BC971-0BAF-4A64-9D58-6449253860C9Q47133431-2EC9E88D-125C-48BF-8AFB-FFD02B3928A4Q50955202-F9B6200A-B21A-4C54-9E14-3E84155C40B9
P2860
Pl(A2) polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Pl(A2) polymorphism of beta(3) ...... e site of microvascular injury
@ast
Pl(A2) polymorphism of beta(3) ...... e site of microvascular injury
@en
Pl(A2) polymorphism of beta(3) ...... e site of microvascular injury
@nl
type
label
Pl(A2) polymorphism of beta(3) ...... e site of microvascular injury
@ast
Pl(A2) polymorphism of beta(3) ...... e site of microvascular injury
@en
Pl(A2) polymorphism of beta(3) ...... e site of microvascular injury
@nl
prefLabel
Pl(A2) polymorphism of beta(3) ...... e site of microvascular injury
@ast
Pl(A2) polymorphism of beta(3) ...... e site of microvascular injury
@en
Pl(A2) polymorphism of beta(3) ...... e site of microvascular injury
@nl
P2093
P356
P1433
P1476
Pl(A2) polymorphism of beta(3) ...... e site of microvascular injury
@en
P2093
P304
P356
10.1161/HC4701.099787
P407
P577
2001-11-27T00:00:00Z